Espay_2018_Mov.Disord_33_1769

Reference

Title : Pimavanserin for Parkinson's Disease psychosis: Effects stratified by baseline cognition and use of cognitive-enhancing medications - Espay_2018_Mov.Disord_33_1769
Author(s) : Espay AJ , Guskey MT , Norton JC , Coate B , Vizcarra JA , Ballard C , Factor SA , Friedman JH , Lang AE , Larsen NJ , Andersson C , Fredericks D , Weintraub D
Ref : Movement Disordersord , 33 :1769 , 2018
Abstract :

BACKGROUND: PD psychosis is often associated with cognitive impairment, including dementia, and involves dopaminergic, serotonergic, and cholinergic mechanisms. OBJECTIVE: To evaluate the differential effect of the antipsychotic pimavanserin, a selective serotonin 2A receptor inverse agonist, in PD psychosis patients with versus without cognitive impairment and in those receiving versus not receiving cognitive-enhancing medications. METHODS: Data from the pivotal randomized clinical trial of pimavanserin for PD psychosis were stratified by (1) screening MMSE score as cognitively impaired (21-24) versus unimpaired (>/=25) and (2) concomitant use versus nonuse of cognitive-enhancing medications. The primary outcome measure was change in the PD-adapted Scale for the Assessment of Positive Symptoms. RESULTS: Mean (pimavanserin vs. placebo) change from baseline was larger in the cognitively impaired (n = 50; -6.62 vs. -0.91; P = 0.002) versus the cognitively unimpaired (n = 135; -5.50 vs. -3.23; p = 0.046) group. The comparable change was -6.04 versus -2.18 (P = 0.012) and -5.66 versus -3.15 (P = 0.041) in patients treated (n = 69) and not treated (n = 116) with concomitant cognitive-enhancing medication. Pimavanserin was similarly tolerated across all cognitive groups with no additional safety concerns identified. Overall adverse event rates were comparable across the concomitant cognitive-enhancing medication groups; however, rates of serious adverse events and discontinuations attributed to adverse events were increased in patients taking cholinesterase inhibitors. CONCLUSIONS: The antipsychotic effect of pimavanserin is robust in PD patients with cognitive impairment and may be enhanced by concomitant cognitive-enhancing medication use. Future prospective studies are needed to confirm these preliminary findings. (c) 2018 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.

PubMedSearch : Espay_2018_Mov.Disord_33_1769
PubMedID: 30387904

Related information

Citations formats

Espay AJ, Guskey MT, Norton JC, Coate B, Vizcarra JA, Ballard C, Factor SA, Friedman JH, Lang AE, Larsen NJ, Andersson C, Fredericks D, Weintraub D (2018)
Pimavanserin for Parkinson's Disease psychosis: Effects stratified by baseline cognition and use of cognitive-enhancing medications
Movement Disordersord 33 :1769

Espay AJ, Guskey MT, Norton JC, Coate B, Vizcarra JA, Ballard C, Factor SA, Friedman JH, Lang AE, Larsen NJ, Andersson C, Fredericks D, Weintraub D (2018)
Movement Disordersord 33 :1769